Company Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases.
The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia.
The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues.
It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease.
The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013.
Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2013 |
| IPO Date | Feb 3, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 87 |
| CEO | Gilmore O’Neill |
Contact Details
Address: 11 Hurley Street Cambridge, Massachusetts 02141 United States | |
| Phone | 617 401 9000 |
| Website | editasmedicine.com |
Stock Details
| Ticker Symbol | EDIT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001650664 |
| CUSIP Number | 28106W103 |
| ISIN Number | US28106W1036 |
| Employer ID | 46-4097528 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Gilmore O'Neill M.D. | President, Chief Executive Officer and Director |
| Dr. Feng Zhang Ph.D. | Co-Founder and Scientific Advisory Board Member |
| Dr. George McDonald Church Ph.D. | Co-Founder and Scientific Advisory Board Member |
| Amy Parison | Senior Vice President and Chief Financial Officer |
| Gregory Whitehead | Executive Vice President and Chief Technical and Quality Officer |
| Dr. Linda C. Burkly Ph.D. | Executive Vice President and Chief Scientific Officer |
| Cristi Barnett | Senior Vice President of Corporate Communications and Investor Relations |
| Damien Grierson J.D. | Senior Vice President, General Counsel and Corporate Secretary |
| Frank Panaccio | Senior Vice President and Chief Business Officer |
| Brieana Buckley | Senior Vice President of Development and Program Leadership |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 7, 2026 | 8-K | Current Report |
| Mar 27, 2026 | 8-K | Current Report |
| Mar 26, 2026 | SCHEDULE 13G/A | Filing |
| Mar 9, 2026 | 10-K | Annual Report |
| Mar 9, 2026 | 8-K | Current Report |
| Feb 27, 2026 | 144 | Filing |
| Dec 1, 2025 | 144 | Filing |
| Nov 10, 2025 | 10-Q | Quarterly Report |
| Nov 10, 2025 | 8-K | Current Report |
| Oct 9, 2025 | 8-K | Current Report |